Ovid Therapeutics Inc (OVID)

06:51 AM

We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance

06:51 AM

May 13, 2026

B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia

May 13, 2026

May 12, 2026

Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo

May 12, 2026

May 12, 2026

Ovid Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada

May 12, 2026

May 12, 2026

OVID Sets Stage for Future Growth with Promising Pipeline Develo - GuruFocus

May 12, 2026

May 12, 2026

Ovid Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 12, 2026

May 12, 2026

Ovid Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2026

May 12, 2026

Ovid Therapeutics Reports Q1 2026 Results, Advances OV329 and OV4071 Clinical Programs, and Expands Pipeline for Pediatric Epilepsy and Psychosis 123 - Minichart

May 12, 2026

May 12, 2026

Ovid Therapeutics stock rises 4% on in-line results, pipeline progress - Investing.com India

May 12, 2026

May 12, 2026

OVID: Advancing novel therapies for seizures and psychosis with strong safety and market potential - TradingView

May 12, 2026

May 12, 2026

Ovid Therapeutics : May 2026 Corporate Presentation - marketscreener.com

May 12, 2026

May 12, 2026

Ovid Therapeutics (NASDAQ: OVID) widens Q1 loss but boosts cash to $165.6M - Stock Titan

May 12, 2026

May 12, 2026

Ovid Therapeutics Inc. 1Q 2026: Revenue $0M, Net loss $17M, EPS $(0.12) — 10-Q Summary - TradingView

May 12, 2026

May 12, 2026

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times

May 12, 2026

May 12, 2026

Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 12, 2026

May 12, 2026

Ovid Therapeutics (NASDAQ: OVID) extends cash runway into 2029 - Stock Titan

May 12, 2026

May 12, 2026

Epilepsy drug shows favorable safety as Ovid adds pediatric seizure studies - Stock Titan

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 10, 2026

Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks - Insider Monkey

May 10, 2026

May 09, 2026

Ovid Therapeutics (OVID) Eps Diluted (TTM) - Zacks Investment Research

May 09, 2026

May 08, 2026

5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey

May 08, 2026

May 08, 2026

Ovid Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

May 08, 2026

May 04, 2026

MSN Money - MSN

May 04, 2026

Apr 29, 2026

Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest - MarketBeat

Apr 29, 2026

Apr 29, 2026

OVID Earnings History & Surprises | EPS & Revenue Results | OVID THERAPEUTICS INC (NASDAQ:OVID) - ChartMill

Apr 29, 2026

Apr 27, 2026

Ovid Therapeutics (NASDAQ: OVID) outlines 2026 virtual meeting, pay and audit votes - Stock Titan

Apr 27, 2026

Apr 27, 2026

SEC Form DEFA14A filed by Ovid Therapeutics Inc. - Quantisnow

Apr 27, 2026

Apr 27, 2026

[ARS] Ovid Therapeutics Inc. SEC Filing - Stock Titan

Apr 27, 2026

Apr 27, 2026

Ovid Therapeutics (NASDAQ: OVID) registers 29.9M resale shares from private placement - Stock Titan

Apr 27, 2026

Apr 27, 2026

[EFFECT] Ovid Therapeutics Inc. SEC Filing - Stock Titan

Apr 27, 2026

Apr 23, 2026

OVID Ovid Therapeutics Inc. far exceeds Q4 2025 EPS expectations, shares rise nearly four percent.Profit Guidance - Cổng thông tin điện tử Tỉnh Sơn La

Apr 23, 2026

Apr 22, 2026

OVID (Ovid Therapeutics) delivers blowout Q4 2025 results, but stock dips slightly amid mild investor profit taking.Deceleration Risk - Xã Thanh Hà

Apr 22, 2026

Apr 21, 2026

29.86M-share resale registration by Ovid Therapeutics (NASDAQ: OVID) - Stock Titan

Apr 21, 2026

Apr 20, 2026

H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy By Investing.com - Investing.com India

Apr 20, 2026

Apr 20, 2026

Ovid Therapeutics receives $53.9 million from warrant exercises By Investing.com - Investing.com India

Apr 20, 2026

Apr 20, 2026

Ovid Therapeutics Boosts Capital Through Warrant Exercises - TipRanks

Apr 20, 2026

Apr 20, 2026

Ovid Therapeutics receives $53.9 million from warrant exercises - Investing.com

Apr 20, 2026

Apr 20, 2026

Ovid Therapeutics sees $53.9M gross proceeds as Series A warrants mostly exercised - TradingView

Apr 20, 2026

Apr 20, 2026

Warrant exercises bring Ovid Therapeutics (NASDAQ: OVID) $53.9M cash - Stock Titan

Apr 20, 2026

Apr 20, 2026

H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy - Investing.com

Apr 20, 2026

Apr 20, 2026

Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Apr 20, 2026

Apr 18, 2026

William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Announces Target Price $5.24 - 富途牛牛

Apr 18, 2026

Apr 17, 2026

LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Apr 17, 2026

Apr 16, 2026

William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - 富途牛牛

Apr 16, 2026

Apr 16, 2026

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN) - The Globe and Mail

Apr 16, 2026

Apr 15, 2026

OVID.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 15, 2026

Apr 15, 2026

OVID Reiterated by Wedbush -- Price Target Maintained at $7.00 - GuruFocus

Apr 15, 2026

Apr 15, 2026

Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential By Investing.com - Investing.com South Africa

Apr 15, 2026

Apr 15, 2026

Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential - Investing.com

Apr 15, 2026

Apr 15, 2026

Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush - MarketBeat

Apr 15, 2026